BACKGROUND Patients diagnosed as diffuse large B cell lymphoma (DLBCL) with CD5 positive normally have a worse outcome and poorly respond to the regulatory treatment strategy. RESULTS We recently reported differently expressed tRFs and their potential target-genes of tRFs in patients with CD5+ R/R DLBCL. Differently expressed tRFs were detected by Illumina NextSeq instrument and the results were verified by quantitative real-time reverse transcription-PCR. tRF2Cancer database was searched to compared with the results. Further research was performed through bio-informatic analysis including gene ontology (GO) and pathway enrichment analyses, etc. A total of 308 tRFs were identified. Two sequences (AS-tDR-008946, AS-tDR-013492) were chosen for further investigated. CONCLUSIONS The results of Bioinformatics analysis revealed that the target genes including NEDD4L and UBA52 and several associated pathways including PI3K/AKT and MAPK/ERK might be involved in the development of CD5+ R/R DLBCL. Our preliminary study on the associated tRFs might provide a valuable measure to explore the pathogenesis and progression of CD5+ R/R DLBCL. REVIEWERS This article was reviewed by Zhen Qing Ye, Nagarajan Raju and Jin Zhuang Dou.

中文翻译：

---

CD5阳性复发和难治性弥漫性大B细胞淋巴瘤中差异表达的tRFs及其潜在临床用途的生物信息学分析。

背景技术诊断为CD5阳性的弥漫性大B细胞淋巴瘤（DLBCL）的患者通常预后较差，对调节治疗策略的反应也较差。结果我们最近报道了在CD5 + R / R DLBCL患者中表达不同的tRF及其可能的tRF靶基因。用Illumina NextSeq仪器检测表达不同的tRF，并通过定量实时逆转录PCR验证结果。搜索了tRF2Cancer数据库并与结果进行了比较。通过生物信息学分析进行了进一步的研究，包括基因本体论（GO）和途径富集分析等。共鉴定了308个tRF。选择了两个序列（AS-tDR-008946，AS-tDR-013492）进行进一步研究。结论生物信息学分析的结果表明，包括NEDD4L和UBA52在内的靶基因以及包括PI3K / AKT和MAPK / ERK在内的几种相关途径可能参与了CD5 + R / R DLBCL的发展。我们对相关tRFs的初步研究可能为探索CD5 + R / R DLBCL的发病机理和进展提供有价值的措施。审阅者本文由Zhen Qing Ye，Nagarajan Raju和Jin Zhuang Dou审阅。